Abstract: The present invention relates to polypeptides comprising (i) a VWF moiety and (ii) an erythrocyte-binding moiety, wherein the polypeptide is capable of binding to blood coagulation factor VIII (FVIII). The erythrocyte-binding moiety may be selected from the group consisting of a peptide ligand, an antibody, an antibody fragment, and a single chain antigen binding domain (scFv). The polypeptides may be provided as a heterodimer. The polypeptides are useful for inducing tolerance to FVIII.

Abstract: This invention provides Factor IX variants, molecules comprising the variants, nucleic acids encoding the variants, compositions comprising the variants or the nucleic acids encoding the variants, and their use in methods for the modulation of hemostasis, for example in the prophylaxis or treatment of hemophilia B. The Factor IX variants have improved biological properties relative to other Factor IX variants and/or relative to wild-type Factor IX.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R5, A and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

Abstract: The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R5, A and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

Abstract: The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.

Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Abstract: A data-processing system having at least one operating memory holding operating data is provided with a protection unit having an execution environment protected from unauthorized access. At least one monitoring logic in the execution environment is connected to the operating memory for monitoring unauthorized modifications, access, or similar protection violations of the operating data stored in the operating memory and for generating an output on detection of such a protection violation. A protection logic in the execution environment holds replacement data capable of replacing the operating data and is connected to the monitoring logic for, on generation of the output, providing to the operating memory the replacement data for the operation or for a substitute operation of the data-processing system.

Abstract: The invention provides alkoxy-crosslinking rubber mixtures (M) which comprise a compound of the general formula (1) M(OR1)n(OSiR23)5-n (1) and polymers with end groups of the general formula (2) —SiR3a(OR4)3-a (2), where M is defined as Nb or Ta, R1, R2; R3 and R4 are each hydrocarbon radicals having 1 to 10 carbon atoms, n is 1, 2, 3 or 4, and a is 0 or 1.

Abstract: Nanosize titanium dioxide having supported thereon metallic platinum are efficient hydrosilylation catalysts whose hydrosilylation activity may be increased by irradiation. The catalysts are prepared by depositing soluble platinum compounds on a titanium dioxide sol or titanium dioxide pigments followed by drying, calcining, and reduction to platinum metal. The catalysts are particularly useful in preparing addition-curable organopolysiloxane elastomers.

Abstract: Ruthenium compounds which have, in their ligand sphere, at least one ?6-bonded arene ligand and a silyl ligand; ruthenium complexes which have, in their ligand sphere, at least one ?6-bonded arene ligand to which is bonded a silyl or siloxy radical directly or via a spacer, and ruthenium complexes which have, in their ligand sphere, at least one ?6-bonded arene ligand and at least one further ligand to which is bonded a silyl or siloxy radical directly or via a spacer are useful as hydrosilylation catalysts.

Abstract: The invention provides alkoxy-crosslinking rubber mixtures (M) which comprise a compound of the general formula (1) M(OR1)n(OSiR23)5-n (1) and polymers with end groups of the general formula (2) —SiR3a(OR4)3-a (2), where M is defined as Nb or Ta, R1, R2; R3 and R4 are each hydrocarbon radicals having 1 to 10 carbon atoms, n is 1, 2, 3 or 4, and a is 0 or 1.

Abstract: Ru(0) complexes containing sulfoxide ligands and aliphatically unsaturated ligands are effective hydrosilylation catalysts useful in particular for addition curing organosilicon compositions.

Abstract: Ru(0) complexes containing sulfoxide ligands and aliphatically unsaturated ligands are effective hydrosilylation catalysts useful in particular for addition curing organosilicon compositions.

Abstract: Hydrosilylatable compositions employ ruthenium compounds with a ligand sphere comprising at least two independent carbon ?-bonded ligands, at least one of these ligands being selected from the group consisting of ?6-bonded arene ligands, ?6-bonded triene ligands, ?4-bonded 1,5-cyclooctadiene ligands and ?4-bonded 1,3,5-cyclooctatriene ligands as a hydrosilylation catalyst.

Abstract: A method for authenticating a software package, which is provided by a software supplier and which contains a software component that can be loaded into a terminal. The software component is provided with a first authentication suffix, which is verified in order to carry out an authenticity test in the terminal. A higher-level authenticating site is provided, performing authenticating measures on the software package to increase security, wherein the measures performed by the higher-level authenticating site include providing the software package with at least one second authentication suffix instead of the first authentication suffix after successful checking of the software package provided by the software provider and including the first authentication suffix in addition to the software component of the software package.

Abstract: Nanosize titanium dioxide having supported thereon metallic platinum are efficient hydrosilylation catalysts whose hydrosilylation activity may be increased by irradiation. The catalysts are prepared by depositing soluble platinum compounds on a titanium dioxide sol or titanium dioxide pigments followed by drying, calcining, and reduction to platinum metal. The catalysts are particularly useful in preparing addition-curable organopolysiloxane elastomers.

Abstract: The invention relates to a vehicle seat comprising at least one gas spring (9) which damps vibration and adjusts the seat height, said gas spring being arranged between a seat frame (1) and a base frame (2), and comprising a valve arrangement (43, 44) for adjusting the pressure in the gas spring (9) and a compressor (45) assigned to the vehicle seat (17, 20, 23), said compressor having a drive motor for feeding compressed gas to the gas spring (9), wherein a belt roller device comprising a belt (11) rolled around an axle (12) is arranged between the seat frame (1) and the base frame (2), the first end (11a) of said belt being attached to a belt roller mechanism (10) arranged on the seat frame (1) and the second end (11b) of said belt being attached to the base frame (2), and a detector (16) which detects a belt rolling movement is attached to the seat frame (1).

Abstract: Ruthenium compounds which have, in their ligand sphere, at least one ?6-bonded arene ligand and a silyl ligand; ruthenium complexes which have, in their ligand sphere, at least one ?6-bonded arene ligand to which is bonded a silyl or siloxy radical directly or via a spacer, and ruthenium complexes which have, in their ligand sphere, at least one ?6-bonded arene ligand and at least one further ligand to which is bonded a silyl or siloxy radical directly or via a spacer are useful as hydrosilylation catalysts.